Literature DB >> 12889994

Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2.

X Wang1, B Liang, V Rebmann, J Lu, E Celis, T Kageshita, H Grosse-Wilde, S Ferrone.   

Abstract

Only three anti-HLA-A monoclonal antibodies (mAbs) have been described in the literature. Two of them recognize determinants shared by only a few HLA-A allospecificities. The third one, mAb 3G11, recognizes a determinant shared by most HLA-A allospecificities. Being an IgM, the latter mAb is not likely to be a useful probe in immunohistochemical reactions and in functional assays. Therefore, in the present study we have characterized the specificity of the mAbs LGIII-147.4.1 and LGIII-220.6.2. The two mAbs that do not share idiotypic determinants recognize distinct but spatially close antigenic determinants expressed on most of the gene products of the HLA-A locus. Specifically, the determinant recognized by mAb LGIII-220.6.2 is expressed on HLA-A1, -A2, -A3, -A26, -A28, -A29, -A30, -A33, -A36, -A74 and -A80 allospecificities. The determinant recognized by mAb LGIII-147.4.1, which appears to be located on the amino-acid residues 79-83 of the heavy chain, is expressed on all HLA-A allospecificities but HLA-A23, -A24, -A25 and -A32. Because of its broad reactivity, the mAb LGIII-147.4.1 was characterized in a number of assays. It was found to be a useful probe to measure the HLA-A antigen level in serum, to assess the HLA-A restriction of cytotoxic T lymphocytes (CTL) and to monitor HLA-A antigen expression in normal and malignant lesions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889994     DOI: 10.1034/j.1399-0039.2003.00087.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Authors:  Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

2.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

3.  Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; William Gooding; Robert L Ferris
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

4.  Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; Liqiang Xi; William Gooding; Tony Godfrey; Robert L Ferris
Journal:  Int J Cancer       Date:  2009-10-15       Impact factor: 7.396

5.  IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells.

Authors:  Yuqing Shen; Mei Xia; Jianqiong Zhang; Lianhong Xu; Jin Yang; Aiqin Chen; Fengqin Miao; Soldano Ferrone; Wei Xie
Journal:  Mol Immunol       Date:  2009-05-09       Impact factor: 4.407

6.  Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Authors:  Silvia Peppicelli; Jessica Ruzzolini; Elena Andreucci; Francesca Bianchini; Filippos Kontos; Teppei Yamada; Soldano Ferrone; Lido Calorini
Journal:  Cancers (Basel)       Date:  2019-08-26       Impact factor: 6.639

7.  HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.

Authors:  Rosa Sottile; Pradeepa N Pangigadde; Thomas Tan; Andrea Anichini; Francesco Sabbatino; Francesca Trecroci; Elvira Favoino; Laura Orgiano; James Roberts; Soldano Ferrone; Klas Kärre; Francesco Colucci; Ennio Carbone
Journal:  Eur J Immunol       Date:  2015-12-20       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.